Благодарности
Данное исследование финансировалась из средств гранта № U01AI078045 Национальных институтов здоровья NIAID [Национальный институт аллергии и инфекционных заболеваний] (Maria A. Croyle). Содержание и мнения, высказанные в этой статье, не обязательно отражают официальную точку зрения Национального института аллергии и инфекционных заболеваний. Авторы хотели бы поблагодарить г-на Стивена С. Шафера (Stephen C. Schafer) за оказанную им отличную техническую помощь в подготовке рисунков, представленных в данной статье. Авторы не заявляют о каких-либо конфликтах или финансовых интересах, которые имели бы непосредственное отношение к содержанию этой статьи.
Ссылки
1. Bray M, Murphy FA. Filovirus research: knowledge expands to meet a growing threat. J Infect Dis. 2007;196(Suppl 2):S438–43.
2. Huang Y, Xu L, Sun Y, Nabel GJ. The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell. 2002; 10(2):307–16.
3. Muhlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication
systems. J Virol. 1999;73(3):2333–42.
4. Volchkov VE, Volchkova VA, Muhlberger E, Kolesnikova LV, Weik M, Dolnik O, Klenk HD. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene
and viral cytotoxicity. Science. 2001;291(5510):1965–9.
5. Bamberg S, Kolesnikova L, Moller P, Klenk HD, Becker S. VP24 of Marburg virus influences formation of infectious particles. J Virol. 2005;79(21):13421–33.
6. Han Z, Boshra H, Sunyer JO, Zwiers SH, Paragas J, Harty RN. Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and
budding. J Virol. 2003;77(3):1793–800.
7. Noda T, Halfmann P, Sagara H, Kawaoka Y. Regions in Ebola virus VP24 that are important for nucleocapsid formation. J Infect Dis. 2007;196(Suppl 2):S247–50.
8. Noda T, Watanabe S, Sagara H, Kawaoka Y. Mapping of the VP40-binding regions of the nucleoprotein of Ebola virus. J Virol. 2007;81(7):3554–62.
9. Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol. 2002;76(10):4855–65.
10. Watanabe S, Watanabe T, Noda T, Takada A, Feldmann H, Jasenosky LD, Kawaoka Y. Production of novel Ebola virus-like particles from cDNAs: an alternative to Ebola virus generation by reverse genetics. J Virol. 2004;78(2):999–1005.
11. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci USA. 1996;93(8):3602–7.
12. Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci USA. 1998;95(10):5762–7.
13. Volchkov VE, Volchkova VA, Muhlberger E, Kolesnikova LV, Weik M, Dolnik O, Klenk HD. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene
and viral cytotoxicity. Science. 2001;291(5510):1965–9.
14. Volchkov VE, Volchkova VA, Slenczka W, Klenk HD, Feldmann H. Release of viral glycoproteins during Ebola virus infection. Virology. 1998;245(1):110–9.
15. Chan SY, Empig CJ, Welte FJ, Speck RF, Schmaljohn A, Kreisberg JF, Goldsmith MA. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell.
2001;106(1):117–26.
16. Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Virol. 2000;74(10):4933–7.
17. Chepurnov AA, Tuzova MN, Ternovoy VA, Chernukhin IV. Suppressive effect of Ebola virus on T cell proliferation in vitro is provided by a 125-kDa GP viral protein. Immunol Lett. 1999; 68(2–3):257–61.
18. Volchkov VE, Blinov VM, Netesov SV. The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses. FEBS Lett. 1992;
305(3):181–4.
19. Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol. 1998;72(4):3155–60.
20. Yang Z, Delgado R, Xu L, Todd RF, Nabel EG, Sanchez A, Nabel GJ. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science. 1998;279(5353):
1034–7.
21. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.
Nat Med. 2000;6(8):886–9.
22. Yaddanapudi K, Palacios G, Towner JS, Chen I, Sariol CA, Nichol ST, Lipkin WI. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J. 2006;20(14):2519–30.
23. Sanchez A, Yang ZY, Xu L, Nabel GJ, Crews T, Peters CJ. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol. 1998;72(8):6442–7.
24. Volchkova VA, Feldmann H, Klenk HD, Volchkov VE. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology. 1998;250(2): 408–14.
25. Ito H, Watanabe S, Takada A, Kawaoka Y. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol. 2001;75(3):1576–80.
26. Radoshitzky SR, Warfield KL, Chi X, Dong L, Kota K, Bradfute SB, Gearhart JD, Retterer C, Kranzusch PJ, Misasi JN, Hogenbirk MA, Wahl-Jensen V, Volchkov VE, Cunningham JM,
Jahrling PB, Aman MJ, Bavari S, Farzan M, Kuhn JH. Ebola virus delta-peptide immunoadhesins inhibit Marburg virus and Ebola virus cell entry. J Virol. 2011;85(17):8502–13.
27. Mehedi M, Falzarano D, Seebach J, Hu X, Carpenter MS, Schnittler HJ, Feldmann H. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol. 2011; 85(11):5406–14.
28. Zaki SR, Goldsmith CS. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol. 1999;235:97–116.
29. Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, Negley D, Mohamadzadeh M, Bavari S, Schmaljohn A. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis. 2003;188(11):1630–8.
30. Mahanty S, Hutchinson K, Agarwal S, Mcrae M, Rollin PE, Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol.
2003;170(6):2797–27801.
31. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, Bray M, Klenk HD, Palese P, Garcia-Sastre A. The Ebola virus VP35 protein inhibits activation of interferon
regulatory factor 3. J Virol. 2003;77(14):7945–56.
32. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, Volchkov VE, Nichol ST, Basler CF. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear
accumulation. J Virol. 2006;80(11):5156–67.
33. Feng Z, Cerveny M, Yan Z, He B. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol. 2007;81(1):
182–92.
34. Halfmann P, Neumann G, Kawaoka Y. The Ebola virus VP24 protein blocks phosphorylation of P38 mitogen-activated protein kinase. J Infect Dis. 2011;204(Suppl 3):S953–6.
35. Schumann M, Gantke T, Muhlberger E. Ebola virus VP35 antagonizes Pkr activity through its C-terminal interferon inhibitory domain. J Virol. 2009;83(17):8993–7.
36. Martinez O, Leung LW, Basler CF. The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge. Antivir Res. 2012;93(3):416–28.
37. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I, Lansoud-Soukate J, Mavoungou E. Inflammatory responses in Ebola virus-infected patients. Clin Exp
Immunol. 2002;128(1):163–8.
38. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P, Fisher-Hoch SP, Mccormick JB, Georges AJ. Defective humoral responses and extensive intravascular
apoptosis are associated with fatal outcome in Ebola virusinfected patients. Nat Med. 1999;5(4):423–6.
39. Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB, Zaki SR, Swanepoel R, Ansari AA, Peters CJ. Markedly elevated levels of interferon (IFN)-gamma, IFNalpha,
interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis. 1999;179(Suppl 1):S188–91.
40. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, Jaax NK, Jahrling PB. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis. 1999;179(Suppl 1): S203–17.
41. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, Scott DP, Kagan E, Jahrling PB, Davis KJ. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol. 2003;163(6):2347–70.
42. Hensley LE, Young HA, Jahrling PB, Geisbert TW. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett. 2002;80(3):169–79.
43. Zampieri CA, Sullivan NJ, Nabel GJ. Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat Immunol. 2007;8(11):1159–64.
44. Leroy EM, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect.
2011;17(7):964–76.
45. Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Caı` Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, et al. Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol. 2013;158(1):301–11.
46. Hayes CG, Burans JP, Ksiazek TG, Del Rosario RA, Miranda ME, Manaloto CR, Barrientos AB, Robles CG, Dayrit MM, Peters CJ. Outbreak of fatal illness among captive macaques in
the Philippines caused by an Ebola-related filovirus. Am J Trop Med Hyg. 1992;46(6):664–71.
47. Jahrling PB, Geisbert TW, Dalgard DW, Johnson ED, Ksiazek TG, Hall WC, Peters CJ. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet. 1990;335(8688): 502–5.
48. Rollin PE, Williams RJ, Bressler DS, Pearson S, Cottingham M, Pucak G, Sanchez A, Trappier SG, Peters RL, Greer PW, Zaki S, Demarcus T, et al. Ebola (subtype Reston) virus among quarantined nonhuman primates recently imported from the Philippines to the United States. J Infect Dis. 1999;179(Suppl 1):S108–14.
49. Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G, Kobinger G. Transmission of Ebola virus from pigs to nonhuman primates. Sci Rep. 2012;2:811.
50. Reed DS, Lackemeyer MG, Garza NL, Sullivan LJ, Nichols DK. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect. 2011;13(11):930–6.
51. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377(9768):849–62.
52. Kuhn JH, Dodd LE, Wahl-Jensen V, Radoshitzky SR, Bavari S, Jahrling PB. Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror. 2011;9(4):361–71.
53. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204(Suppl 3):S810–6.
54. Paessler S, Walker DH. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol Mech Dis. 2013;8:411–40.
55. Lupton HW, Lambert RD, Bumgardner DL, Moe JB, Eddy GA. Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet. 1980;2(8207):1294–5.
56. Chupurnov AA, Chernukhin IV, Ternovoi VA, Kudoiarova NM, Makhova NM, Azaev MS, Smolina MP. Attempts to develop a vaccine against Ebola fever. Vopr Virusol. 1995;40(6):257–60.
57. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000;408(6812):605–9.
58. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human
primates. Nature. 2003;424(6949):681–4.
59. Richardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, Feldmann H, Kobinger GP. Enhanced protection against Ebola J. H. Choi, M. A. Croyle virus mediated by an improved adenovirus-based vaccine. PloS One. 2009;4(4):e5308.
60. Choi JH, Schafer SC, Zhang L, Kobinger GP, Juelich T, Freiberg AN, Croyle MA. A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs. Mol Pharm. 2012;9(1):156–67.
61. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, Feldmann H, Kobinger GP. Nasal delivery of an adenovirusbased vaccine bypasses pre-existing immunity to the vaccine
carrier and improves the immune response in mice. PLoS One. 2008;3(10):e3548.
62. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, Wolfe ND, Aste-Amezaga M, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010;28(4):950–7.
63. Pilankatta R, Chawla T, Khanna N, Swaminathan S. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines. J Med Virol. 2010;82(3):407–14.
64. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, Robbins PD, Gambotto A. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States. Clin Diagn Lab Immunol. 2004;11(2):351–7.
65. Aldhamen YA, Seregin SS, Amalfitano A. Immune recognition of gene transfer vectors: focus on adenovirus as a paradigm. Front Immunol. 2011;2:40. doi:10.3389/fimmu.2011.00040.
66. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, Custers J, Vellinga J, Hendriks J, Jahrling P, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against Ebola virus challenge. J Virol. 2011;85(9):4222–33.
67. Patel A, Tikoo S, Kobinger G. A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model. PLoS One 2010. 5(12). doi:10.1371/journal.pone.0015301.
68. Singh N, Pandey A, Jayashankar L, Mittal SK. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human
adenovirus. Mol Ther. 2008;16(5):965–71.
69. Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, Jones S, Wilson JM. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006;346(2):394–401.
70. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, et al, and the VRC 205 Study
Team. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010;29(2):304–13.
71. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R, Volchkov V, Klenk HD, Feldmann H, Stroher U. Properties of replication-competent vesicular stomatitis virus
vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004;78(10):5458–65.
72. Tsuda Y, Safronetz D, Brown K, Lacasse R, Marzi A, Ebihara H, Feldmann H. Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection. J Infect Dis. 2011;204(Suppl 3): S1090–7.
73. Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011;204(Suppl 3):S1075–81.
74. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, Stroher U, Feldmann H, Jones SM. Mucosal immunization of cynomolgus macaques with the VSVdeltaG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One. 2009;4(5):e5547.
75. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, Stroher U, Fritz EA, Hensley LE, Jones SM, Feldmann H. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008;26(52):6894–900.
76. Geisbert TW, Daddario-Dicaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, Hensley LE, Feldmann H, Jones SM. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol. 2008;82(11):5664–8.
77. Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, Melito P, Bray M, Klenk HD, Feldmann H. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis. 2007;196(Suppl 2):S404–12.
78. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11(7): 786–90.
79. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11(7):786–90.
80. Feldmann H, Jones SM, Daddario-Dicaprio KM, Geisbert JB, Stro¨her U, Grolla A, Bray M, Fritz EA, Fernando L, Feldmann F, Hensley LE, Geisbert TW. Effective post-exposure treatment
of Ebola infection. PLoS Pathog. 2007;3(1):e2.
81. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, Paragas J, Matthias L, Smith MA, Jones SM, Hensley LE, Feldmann H, Jahrling PB. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008;4(11): e1000225.
82. Mire CE, Miller AD, Carville A, Westmoreland SV, Geisbert JB, Mansfield KG, Feldmann H, Hensley LE, Geisbert TW. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012;6(3):e1567. doi: 10.1371/journal.pntd.0001567.
83. Gunther S, Feldmann H, Geisbert TW, Hensley LE, Rollin PE, Nichol ST, Stroher U, Artsob H, Peters CJ, Ksiazek TG, Becker S, Ter Meulen J, Olschlager S, Schmidt-Chanasit J, Sudeck H,
Burchard GD, Schmiedel S. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis. 2011;204(Suppl 3):S785–90.
84. Bukreyev A, Skiadopoulos MH, Murphy BR, Collins PL. Nonsegmented negative-strand viruses as vaccine vectors. J Virol. 2006;80(21):10293–306.
85. Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, Collins PL, Sanchez A. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol. 2006;80(5):2267–79.
86. Bukreyev AA, Dinapoli JM, Yang L, Murphy BR, Collins PL. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology. 2010;399(2):290–8.
87. Bukreyev A, Marzi A, Feldmann F, Zhang L, Yang L, Ward JM, Dorward DW, Pickles RJ, Murphy BR, Feldmann H, Collins PL. Ebola Vaccines and Therapeutics
Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology. 2009;
383(2):348–61.
88. Carroll SA, Towner JS, Sealy TK, Mcmullan LK, Khristova ML, Burt FJ, Swanepoel R, Rollin PE, Nichol ST. Molecular evolution of viruses of the family filoviridae based on 97 wholegenome sequences. J Virol. 2013;5(5):2608–16.
89. Hensley L, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, Fabozzi G, Nichol ST, Ksiazek TG, Rollin PE, Wahl-Jensen V, Bailey M, Jahrling PB, Roederer M, Koup RA, Sullivan
NJ. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebola virus species. PLoS Pathog. 2010;6(5):e1000904.
90. Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect
Dis. 2011;204(Suppl 3):1066–74.
91. Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, Dye JM, Holman DH, Dong JY. Protection of nonhuman primates against two species of Ebola virus infection with a single
complex adenovirus vector. Clin Vaccine Immunol. 2010; 17(4):572–81.
92. Geisbert TW, Geisbert JB, Leung A, Daddario-Dicaprio KM, Hensley LE, Grolla A, Feldmann H. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol. 2009;83(14): 7296–304.
93. Ndhlovu ZM, Piechocka-Trocha A, Vine S, Mcmullen A, Koofhethile KC, Goulder PJ, Ndung’u T, Barouch DH, Walker BD. Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8? T cells. J Immunol. 2011;186(12): 6914–24.
94. Santra S, Liao HX, Zhang R, Muldoon M, Watson S, Fischer W, Theiler J, Szinger J, Balachandran H, Buzby A, Quinn D, Parks RJ, Tsao CY, Carville, et al. Mosaic vaccines elicit CD8? T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med. 2010;16(3):324–8.
95. Barouch DH, O’brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, Sun YH, La Porte A, Riggs AM, Lynch DM, Clark SL, Backus K, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med. 2010;16(3):319–23.
96. Zahn R, Gillisen G, Roos A, Koning M, Van Der Helm E, Spek D, Weijtens M, Grazia Pau M, Radosˇevic´ K, Weverling GJ, Custers J, Vellinga J, et al. Ad35 and Ad26 vaccine vectors
induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS One. 2012;7(12):e44115.
97. Fenimore PW, Muhammad MA, Fischer WM, Foley BT, Bakken RR, Thurmond JR, Yusim K, Yoon H, Parker M, Hart MK, Dye JM, Korber B, Kuiken C. Designing and testing broadly protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage. PLoS One. 2012;7(10):e4469.
98. Phoolcharoen W, Dye JM, Kilbourne J, Piensook K, Pratt WD, Arntzen CJ, Chen Q, Mason HS, Herbst-Kralovetz MM. A nonreplicating subunit vaccine protects mice against lethal
Ebola virus challenge. Proc Natl Acad Sci USA. 2011;108(51): 20695–700.
99. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. BMJ. 1977;2(6086):541–4.
100. Kudoyarova-Zubavichene NM, Sergeyev NN, Chepurnov AA, Netesov SV. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis.
1999;179(Suppl 1):S218–23.
101. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, Colebunders R, Muyembe-Tamfum JJ. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis. 1999;179(Suppl 1):S18–23.
102. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis. 2007;196(Suppl
2):S400–3.
103. Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, Jahrling PB, Parren PW, Burton DR. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 2007;3(1):e9.
104. Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, Sullivan NJ. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology. 2010;401(2):228–35.
105. Qiu X, Alimonti JB, Melito PL, Fernando L, Stroher U, Jones SM. Characterization of Zaire Ebola virus glycoprotein-specific monoclonal antibodies. Clin Immunol. 2011;141(2):218–27.
106. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, Kobinger GP. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012;4(138): 138ra81.
107. Qiu X, Fernando L, Melito PL, Audet J, Feldmann H, Kobinger G, Alimonti JB, Jones SM. Ebola Gp-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis. 2012;6(3):e1575.
108. Kondratowicz AS, Lennemann NJ, Sinn PL, Davey RA, Hunt CL, Moller-Tank S, Meyerholz DK, Rennert P, Mullins RF, Brindley M, Sandersfeld LM, Quinn K, Weller M, Mccray PB, Chiorini J, Maury W. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci USA. 2011;108(20): 8426–31.
109. Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet NP, Majgier-Baranowska H, Williams JD, Patel I, Moir DT, Bavari S, Ray R, Farzan MR, Rong L, Bowlin TL. Identification of a small-molecule entry inhibitor for filoviruses. J Virol. 2011;85(7):3106–19.
110. Coˆte´ M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J. Small molecule inhibitors reveal Niemann-Pick C1 is essential for
Ebola virus infection. Nature. 2011;477(7364):344–8.
111. King G, Sharom FJ. Proteins that bind and move lipids: MsbA and NPC1. Crit Rev Biochem Mol Biol. 2012;47(1):75–95.
112. Lee K, Ren T, Coˆte´ M, Gholamreza B, Misasi J, Bruchez A, Cunningham J. Inhibition of Ebola virus infection: identification of Niemann-Pick C1 as the target by optimization of a chemical probe. ACS Med Chem Lett. 2013;4(2):239–43.
113. Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, Johansen LM, White JM. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit
Ebola virus entry and infection. PLoS One. 2013;8(2):e56265. doi:10.1371/journal.pone.0056265.
114. Miller EH, Harrison JS, Radoshitzky SR, Higgins CD, Chi X, Dong L, Kuhn JH, Bavari S, Lai JR, Chandran K. Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. J Biol
Chem. 2011;286(18):15854–61.
115. Spurgers KB, Alefantis T, Peyser BD, Ruthel GT, Bergeron AA, Costantino JA, Enterlein S, Kota KP, Boltz RC, Aman MJ, Delvecchio VG, Bavari S. Identification of essential filovirionassociated host factors by serial proteomic analysis and RNAi screen. Mol Cell Proteomics. 2010;9(12):2690–703.
116. Barrientos LG, Rollin PE. Release of cellular proteases into the acidic extracellular milieu exacerbates Ebola virus-induced cell damage. Virology. 2007;358(1):1–9.
117. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science. 2005;308(5728):1643–5.
118. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol. 2006;80(8):4174–8.
119. Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA. 2001;98(12):6895–900.
120. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis. 1989;11(Suppl 4):S750–61.
121. Ignat’ev GM, Strel’tsova MA, Agafonov AP, Kashentseva EA, Prozorovskii NS. Experimental study of possible treatment of Marburg hemorrhagic fever with desferal, ribavirin, and homologous interferon. Vopr Virusol. 1996;41(5):206–9.
122. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-Dicaprio K, Fritz EA, Jahrling PB, Mcclintock K, Phelps JR, Lee AC, Judge A, Jeffs LB, Maclachlan I. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis.
2006;193(12):1650–7.
123. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, De Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375(9729): 1896–905.
124. Garcia M, Cooper A, Shi W, Bornmann W, Carrion R, Kalman D, Nabel GJ. Productive replication of Ebola virus is regulated by the C-Abl1 tyrosine kinase. Sci Transl Med. 2012;4(123): 123ra24. doi:10.1126/scitranslmed.3003500.
125. Warren TK, Shurtleff AC, Bavari S. Advanced morpholino oligomers: a novel approach to antiviral therapy. Antiviral Res. 2012;94(1):80–8.
126. Dirin M, Winkler J. Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. Expert Opin Biol Ther. 2013. Epub ahead of print.
127. Swenson DL, Warfield KL, Warren TK, Lovejoy C, Hassinger JN, Ruthel G, Blouch RE, Moulton HM, Weller DD, Iversen PL, Bavari S. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother. 2009;53(5):2089–99.
128. Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, Stein DA, Aman MJ, Iversen PL, Bavari S. Genespecific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2006;2(1):e1.
129. Iversen PL, Warren TK, Wells JB, Garza NL, Mourich DV, Welch LS, Panchal RG, Bavari S. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola
virus and Marburg virus infections. Viruses. 2012;4(11): 2806–30.
130. Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med. 2010;16(9):991–4.
131. Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, Yunus AS, Kinch MS, Goldblatt M, Aman MJ, Bavari S. Antiviral activity of a small-molecule inhibitor of filovirus
infection. Antimicrob Agents Chemother. 2010;54(5):2152–9.
132. Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, Luo G, Nelson EA, Li L, Huang Z, Murray M, Ellis WY, Hensley L, Christopher-Hennings J, Olinger GG, Goldblatt M. FGI-104: a broad-spectrum small molecule inhibitor of viral infection. Am J Transl Res. 2009;1(1):87–98.
133. Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, Stavale E, Wang P, Chang S, Tang Q, Porter K, Goldblatt M, Bavari S. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 2009;83(3):245–51.
134. Bradfute SB, Warfield KL, Bray M. Mouse models for filovirus infections. Viruses. 2012;4(9):1477–508.
135. Subbotina E, Dadaeva A, Kachko A, Chepurnov A. Genetic factors of Ebola virus virulence in guinea pigs. Virus Res. 2010;153(1):121–33.
136. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, Hensley LE. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol. 2003;163(6):2371–82.
137. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis. 1998;178(3):651–61.
138. Bray M. The role of the type I interferon response in the resistance of mice to filovirus infection. J Gen Virol. 2001;82(Pt 6):1365–73.
139. Bray M, Raymond JL, Geisbert T, Baker RO. 3-Deazaneplanocin a induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res. 2002;55(1):151–9.
140. Bray M, Driscoll J, Huggins JW. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-Lhomocysteine hydrolase inhibitor. Antiviral Res. 2000;45(2):
135–47.
141. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, Jaax NK, Huggins JW, Leduc JW, Peters CJ. Evaluation of immune globulin and recombinant interferon-Alpha2b for
treatment of experimental Ebola virus infections. J Infect Dis. 1999;179(Suppl 1):S224–34.
142. Markin VA, Mikhailov VV, Krasnianskii VP, Borisevich IV, Firsova IV. Developing principles for emergency prevention and treatment of Ebola fever. Vopr Virusol. 1997;42(1):31–4.
143. Kolokoltsov AA, Davidovich IA, Streltsova MA, Nesterov AE, Agafonova OA, Agafonov AP. The use of interferon for emergency prophylaxis of Marburg hemorrhagic fever in monkeys.
Bull Exp Biol Med. 2001;132(1):686–8.
144. Panchal RG, Reid SP, Tran JP, Bergeron AA, Wells J, Kota KP, Aman J, Bavari S. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. Antiviral Res. 2012;93(1):23–9.
145. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 2003;188(11):1618–29.
146. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet. 2003;362(9400):1953–8.
147. Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T, Daddario-Dicaprio KM, Cassell GH, Jahrling PB, Geisbert TW. Recombinant human activated protein C for the
postexposure treatment of Ebola hemorrhagic fever. J Infect Dis. 2007;196(Suppl 2):S390–9.
148. Mungall D. rNAPc2. Nuvelo. Curr Opin Investig Drugs. 2004;5(3):327–33.
149. Ranieri V, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Ga°rdlund B, Marshall JC, Rhodes A, Artigas A, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055–64.
150. Food and Drug Administration. Voluntary withdrawal of Xigris (drotrecogin alfa (activated)) due to failure to show a survival benefit. 2011 [cited 2013 May 1]. http://www.fda.gov/drugs/drugsafety/ucm277114.htm.
151. Foged C. siRNA delivery with lipid-based systems: promises and pitfalls. Curr Top Med Chem. 2012;12(2):97–107.
152. Jiskoot W, Randolph TW, Volkin DB, Middaugh CR, Schoneich C, Winter G, Friess W, Crommelin DJ, Carpenter JF. Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J Pharm Sci. 2012;101(3):946–54.
153. Shaikh R, Raj Singh TR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. J Pharm Bioallied Sci. 2011;3(1):89–100.
154. Leucuta SE. Systemic and biophase bioavailability and pharmacokinetics of nanoparticulate drug delivery systems. Curr Drug Deliv. 2013;10(2):208–40.
155. Khutoryanskiy VV. Advances in mucoadhesion and mucoadhesive polymers. Macromol Biosci. 2011;11(6):748–64.
156. Das Neves J, Bahia MF, Amiji MM, Sarmento B. Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale. Expert Opin Drug Deliv. 2011;8(8):1085–104.
157. Laffleur F, Bernkop-Schnu¨rch A. Thiomers: promising platform for macromolecular drug delivery. Future Med Chem. 2013; 5(5):511–22.
158. Hauptstein S, Bernkop-Schnu¨rch A. Thiomers and thiomerbased nanoparticles in protein and DNA drug delivery. Expert Opin Drug Deliv. 2012;9(9):1069–81.
159. Aungst BJ. Absorption enhancers: applications and advances. AAPS J. 2012;14(1):10–8.
160. Hamman J, Steenekamp J. Excipients with specialized functions for effective drug delivery. Expert Opin Drug Deliv. 2012;9(2): 219–30.
161. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988;55(6):1189–93.
162. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem. 1994;269(14):10444–50.
163. Gooding M, Browne LP, Quinteiro FM, Selwood DL. siRNA delivery: from lipids to cell-penetrating peptides and their mimics. Chem Biol Drug Des. 2012;80(6):787–809.
164. Sen K, Mandal M. Second generation liposomal cancer therapeutics: transition from laboratory to clinic. Int J Pharm. 2013; 448(1):28–43.
165. Musacchio T, Torchilin VP. Recent developments in lipid-based pharmaceutical nanocarriers. Front Biosci. 2011;16:1388–412.
166. Pardeshi C, Rajput P, Belgamwar V, Tekade A, Patil G, Chaudhary K, Sonje A. Solid lipid based nanocarriers: an overview. Acta Pharm. 2012;62(4):433–72.
167. Lim SB, Banerjee A, O¨ nyu¨ksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release. 2012; 163(1):34–45.
168. Van Rooijen N, Van Nieuwmegen R. Liposomes in immunology: the immune response against antigen-containing liposomes. Immunol Commun. 1977;6(5):489–98.
169. Hsu MJ, Juliano RL. Interactions of liposomes with the reticuloendothelial system. II: Nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages. Biochim Biophys Acta. 1982;720(4):411–9.
170. Shahum E, The´rien HM. Liposomal adjuvanticity: effect of encapsulation and surface-linkage on antibody production and proliferative response. Int J Immunopharmacol. 1995;17(1):
9–20.
171. Agrewala JN, Owais M, Gupta CM, Mishra GC. Antigen incorporation into liposomes results in the enhancement of Il-4 and IgG1 secretion: evidence for preferential expansion of Th-2 cells. Cytokines Mol Ther. 1996;2(1):59–65.
172. Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine. 2012;30(13):2256–72.
173. Christensen D, Korsholm KS, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines. 2011;10(4):513–21.
174. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed. 2012;7:49–60.
175. Yoo JW, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov. 2011;10(7):521–35.
176. Salmaso S, Caliceti P, Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv. 2013. Epub ahead of print.
177. Webster DM, Sundaram P, Byrne ME. Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm. 2013;84(1):1–20.
178. Mandal B, Bhattacharjee H, Mittal N, Sah H, Balabathula P, Thoma LA, Wood GC. Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine.
2013;9(4):474–91.
179. Hudson D, Margaritis A., Biopolymer nanoparticle production for controlled release of biopharmaceuticals. Crit Rev Biotechnol. 2013. Epub ahead of print.
180. Balmayor ER, Azevedo HS, Reis RL. Controlled delivery systems: from pharmaceuticals to cells and genes. Pharm Res. 2011;28(6):1241–58.
181. Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—a review. Int J Pharm. 2011;
415(1–2):34–52.
182. Naeye B, Raemdonck K, Remaut K, Demeester J, De Smedt SC. Matrix systems for siRNA delivery. Curr Top Med Chem. 2012;12(2):89–96.
183. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pre´at V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505–22.
184. Lv Y, Tan T, Svec F, Molecular imprinting of proteins in polymers attached to the surface of nanomaterials for selective recognition of biomacromolecules. Biotechnol Adv. 2013. Epub ahead of print.
185. Cheong WJ, Yang SH, Ali F. Molecular imprinted polymers for separation science: a review of reviews. J Sep Sci. 2013;36(3): 609–28.
186. Wrenn SP, Dicker SM, Small EF, Dan NR, Mleczko M, Schmitz G, Lewin PA. Bursting bubbles and bilayers. Theranostics. 2012;2(12):1140–59.
187. Cheng R, Meng F, Deng C, Klok HA, Zhong Z. Dual and multistimuli responsive polymeric nanoparticles for programmed sitespecific drug delivery. Biomaterials. 2013;34(14):3647–57.
188. Gibson MI, O’reilly RK, To aggregate, or not to aggregate? Considerations in the design and application of polymeric thermally-responsive nanoparticles. Chem Soc Rev. 2013. Epub
ahead of print.
189. Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, Reimann KA, Bao S, Rao S, Roederer M, Jahrling PB, Koup RA, Nabel GJ. CD8? cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med. 2011;17(9):1128–31.
190. Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, Grazia-Pau M, Custers J, Jahrling P, Goudsmit J, Koup R, J. H. Choi, M. A. Croyle Sullivan NJ. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol. 2010;84(19):10386–94.
191. Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, Murphy BR, Collins PL, Sanchez A. Successful topical respiratory tract immunization of primates against Ebola virus.
J Virol. 2007;81(12):6379–88.
192. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 1998;251(1):28–37.
193. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect
Dis. 2007;196(Suppl 2):S430–7.
194. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol. 2002;76(12):6408–12.
Материал подготовлен информационно-аналитическим отделом ФБУН ГНЦ ВБ «Вектор» |
